71 reports of this reaction
4.2% of all BIVALIRUDIN reports
#4 most reported adverse reaction
HEPARIN INDUCED THROMBOCYTOPENIA is the #4 most commonly reported adverse reaction for BIVALIRUDIN, manufactured by Accord Healthcare, Inc.. There are 71 FDA adverse event reports linking BIVALIRUDIN to HEPARIN INDUCED THROMBOCYTOPENIA. This represents approximately 4.2% of all 1,699 adverse event reports for this drug.
Patients taking BIVALIRUDIN who experience heparin induced thrombocytopenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPARIN INDUCED THROMBOCYTOPENIA is moderately reported among BIVALIRUDIN users, representing a notable but not dominant share of adverse events.
In addition to heparin induced thrombocytopenia, the following adverse reactions have been reported for BIVALIRUDIN:
The following drugs have also been linked to heparin induced thrombocytopenia in FDA adverse event reports:
HEPARIN INDUCED THROMBOCYTOPENIA has been reported as an adverse event in 71 FDA reports for BIVALIRUDIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPARIN INDUCED THROMBOCYTOPENIA accounts for approximately 4.2% of all adverse event reports for BIVALIRUDIN, making it a notable side effect.
If you experience heparin induced thrombocytopenia while taking BIVALIRUDIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.